Current stock page

Catalysts

IQV Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - Diagnostics & ResearchScore data as of Sep 4, 2026

IQV

Catalysts
IQVIA Holdings Inc.
Healthcare· Medical - Diagnostics & Research
AIQ Score
NeutralAIQ Edge 6/10
Low Priority
Above Peers
Score data as of Sep 4, 2026
Last price
$267.77
-$3.85 (-1.42%)
Latest market quote
Momentum78
Value54
Quality34
Risk Resilience50
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 3, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 53/100

Momentum 78/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 7, 2026 · Sentiment 33.87%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 78/100AIQ Edge 6/10 Above Peers
Beat rate
100%
8 of 8 reported periods
Average surprise
+1.6%
Across covered historical reports
Latest result
+4.0%
Jul 28, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Jul 28, 2026$3.03$3.15+4.0%$4.3B$4.37B
May 5, 2026$2.82$2.90+2.8%$4.1B$4.15B
Feb 5, 2026$3.40$3.42+0.6%$4.24B$4.36B
Oct 28, 2025$2.98$3.00+0.7%$4.08B$4.1B
Jul 22, 2025$2.77$2.81+1.4%$3.97B$4.02B
May 6, 2025$2.63$2.70+2.7%$3.77B$3.83B
Feb 6, 2025$3.11$3.12+0.3%$3.93B$3.96B
Oct 31, 2024$2.82$2.84+0.7%$3.87B$3.9B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
18
Buy
3
Hold
12-month analyst target
$234.82
-12.31% versus current price
Based on 8 analyst observations. Targets are estimates, not predictions.
Low target
$185.00
-30.91% vs latest price
Average target
$234.82
-12.31% vs latest price
High target
$287.00
+7.18% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 3, 2026

Next known earnings or reporting date.

EPS estimate$3.25

Current analyst expectation for the upcoming report.

Revenue estimate$4.36B

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score78

Where event reaction would show up first.

AIQ score53/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
8
Average target
$234.82
Target upside
-12.31%
Target range
$185.00 - $287.00
90-day revisions
3

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
5
Neutral
0
Negative
0
gurufocus.com · Sep 5, 2026

IQVIA (IQV) Insider James Berkshire Sells 2,668 Shares

James Berkshire, an insider at IQVIA Holdings Inc (IQV), recently sold 2,668 shares of the company's stock, according to a SEC Filing dated 2026-09-02. Followin

gurufocus.com · Sep 3, 2026

IQV Looks 9.6% Overvalued on GF Value™ as AI-Driven Clinical Innovation Unfolds

On September 03, 2026, IQVIA Holdings Inc (NYSE: IQV) announced the launch of IQVIA Predictive Clinical Development, an AI-powered platform designed to accelera

finance.yahoo.com · Aug 21, 2026

IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish?

Despite already outperforming the broader market over the past year, IQVIA continues to enjoy strong backing from Wall Street, with analysts remaining highly optimistic about the stock’s future prospects.

finance.yahoo.com · Aug 4, 2026

The Backlog Tells the Real Story: Inside IQVIA’s Blowout Q2

The global healthcare ecosystem in 2026 is leading to a strong recovery in clinical research, with global pharma R&D investment topping $250 billion and the clinical research organization (CRO) market rising to $72 billion at roughly a 9% annual pace. As biopharma companies move capital into complex biologic pipelines, AI-powered trial improvement, and practical data […]

finance.yahoo.com · Aug 2, 2026

An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know

This insider disposed of 16% of direct holdings at $245.21 per share, while maintaining nearly 3,000 shares valued at $740,000.

Open full news and sentiment

IQV Catalysts FAQ

What are the next catalysts for IQV stock?

IQV's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move IQV stock?

Upcoming events that could move IQV include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could IQV's next earnings report affect the stock?

IQV's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive IQV stock higher?

IQV could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt IQV stock?

IQV could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.